Polymorphic ventricular tachycardia (a.k.a. Torsades de Pointes) is best treated with intravenous magnesium. Patients with a prolonged QT interval have a higher risk of developing polymorphic VT.
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare genetic ventricular tachycardia which can result in sudden cardiac death and/or syncope in young individuals with structurally ...
Two genes are clearly associated with CPVT (RyR2 autosomal dominant and CASQ2 autosomal recessive). Triadin and calmodulin mutations have been shown in possible CPVT cases and in one family with ...
Nashville, TN - In one of the first studies to look at the long-term effects of dofetilide (Tikosyn? - Pfizer) in patients with left ventricular dysfunction and implantable cardioverter-defibrillators ...
Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results